Plasma adiponectin levels and risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction: large-scale observational and Mendelian randomization evidence
- 28 October 2023
- journal article
- research article
- Published by Oxford University Press (OUP) in Cardiovascular Research
- Vol. 120 (1) , 95-107
Abstract
Aims: Adiponectin may play an important protective role in heart failure and associated cardiovascular diseases. We hypothesized that plasma adiponectin is associated observationally and causally, genetically with risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. Methods and results: In the Copenhagen General Population Study, we examined 30 045 individuals with plasma adiponectin measurements observationally and 96 903 individuals genetically in one-sample Mendelian randomization analyses using five genetic variants explaining 3% of the variation in plasma adiponectin. In the HERMES, UK Biobank, The Nord-Trøndelag Health Study (HUNT), deCODE, the Michigan Genomics Initiative (MGI), DiscovEHR, and the AFGen consortia, we performed two-sample Mendelian randomization analyses in up to 1 030 836 individuals using 12 genetic variants explaining 14% of the variation in plasma adiponectin. In observational analyses modelled linearly, a 1 unit log-transformed higher plasma adiponectin was associated with a hazard ratio of 1.51 (95% confidence interval: 1.37–1.66) for heart failure, 1.63 (1.50–1.78) for atrial fibrillation, 1.21 (1.03–1.41) for aortic valve stenosis, and 1.03 (0.93–1.14) for myocardial infarction; levels above the median were also associated with an increased risk of myocardial infarction, and non-linear U-shaped associations were more apparent for heart failure, aortic valve stenosis, and myocardial infarction in less-adjusted models. Corresponding genetic, causal risk ratios were 0.92 (0.65–1.29), 0.87 (0.68–1.12), 1.55 (0.87–2.76), and 0.93 (0.67–1.30) in one-sample Mendelian randomization analyses, and no significant associations were seen for non-linear one-sample Mendelian randomization analyses; corresponding causal risk ratios were 0.99 (0.89–1.09), 1.00 (0.92–1.08), 1.01 (0.79–1.28), and 0.99 (0.86–1.13) in two-sample Mendelian randomization analyses, respectively. Conclusion: Observationally, elevated plasma adiponectin was associated with an increased risk of heart failure, atrial fibrillation, aortic valve stenosis, and myocardial infarction. However, genetic evidence did not support causality for these associations.Keywords
Funding Information
- Research Foundation for Health Research
- Director Kurt Bønnelycke and Mrs. Grethe Bønnelycke Foundation
- BigData@Heart (116074)
- Wellcome Trust (225790/Z/22/Z)
- United Kingdom Research and Innovation Medical Research Council (MC_UU_00002/7)
- British Heart Foundation (RG/13/13/30194, RG/18/13/33946, RE/18/1/34212)
- NIHR (BRC-1215-20014)
- Department of Health and Social Care
This publication has 56 references indexed in Scilit:
- Serum total adiponectin level and the risk of cardiovascular disease in general population: A meta-analysis of 17 prospective studiesAtherosclerosis, 2013
- Adipose Tissue Biology and CardiomyopathyCirculation Research, 2012
- The Effect of Elevated Body Mass Index on Ischemic Heart Disease Risk: Causal Estimates from a Mendelian Randomisation ApproachPLOS Medicine, 2012
- Novel Loci for Adiponectin Levels and Their Influence on Type 2 Diabetes and Metabolic Traits: A Multi-Ethnic Meta-Analysis of 45,891 IndividualsPLOS Genetics, 2012
- Bias in causal estimates from Mendelian randomization studies with weak instrumentsStatistics in Medicine, 2011
- Clear detection of ADIPOQ locus as the major gene for plasma adiponectin: Results of genome-wide association analyses including 4659 European individualsAtherosclerosis, 2010
- A Genome-Wide Association Study Reveals Variants in ARL15 that Influence Adiponectin LevelsPLOS Genetics, 2009
- Mendelian randomization: Using genes as instruments for making causal inferences in epidemiologyStatistics in Medicine, 2008
- Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actionsNature Medicine, 2007
- Adiponectin protects against myocardial ischemia-reperfusion injury through AMPK- and COX-2–dependent mechanismsNature Medicine, 2005